ArticleInvestigational new drugs2021

NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.

Renata Scopim-Ribeiro et al.PubMed ↗Publisher ↗

No numbers read from the abstract.